Levotiroxina Sanofi (Levothyroxine Sodium)

Levothyroxine sodium is a synthetic form of the natural hormone thyroxine (T4). After entering the bloodstream, it binds to nuclear thyroid hormone receptors in target cells, influencing gene expression that raises basal metabolic rate, enhances protein synthesis, and regulates growth and development throughout the body.

The dose of Levotiroxina Sanofi is individualized by the prescribing clinician based on the patient’s age, weight, severity of thyroid deficiency, cardiac status, and laboratory thyroid‑stimulating hormone (TSH) levels. No fixed regimen is provided; the prescriber determines the appropriate amount and infusion rate.

Safety data for levothyroxine sodium in pregnancy and lactation are limited. It should be used only when clearly indicated, after a careful risk‑benefit assessment by the treating physician. If prescribed, close monitoring of maternal thyroid function and fetal development is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Levotiroxina Sanofi delivers levothyroxine intravenously, offering rapid hormone replacement compared with oral levothyroxine tablets, which require gastrointestinal absorption. Compared with liothyronine (T3) preparations, levothyroxine has a longer half‑life and provides a more stable, physiologic hormone profile, making it the preferred choice for most replacement therapies.

Store Levotiroxina Sanofi at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Do not freeze. Inspect the container for any signs of contamination before use.

Levotiroxina Sanofi is given as an intravenous infusion. The solution is added to a compatible IV fluid bag or syringe and administered over a period determined by the prescribing clinician, typically ranging from a few minutes to several hours, depending on the clinical situation.

The most serious risks include cardiac arrhythmias, angina or myocardial infarction in patients with underlying heart disease, severe allergic reactions (anaphylaxis), and overt hyperthyroidism leading to rapid weight loss, anxiety, tremor, and bone loss. Immediate medical attention is required if any of these occur.

Levotiroxina Sanofi should be avoided in patients with untreated adrenal insufficiency, uncorrected thyrotoxicosis, or known hypersensitivity to levothyroxine or any component of the formulation. Caution is also advised for individuals with recent myocardial infarction or uncontrolled cardiovascular disease.